Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

SP, Treon; J, Gustine; K, Meid; G, Yang; L, Xu; X, Liu; M, Demos; A, Kofides; N, Tsakmaklis; JG, Chen; M, Munshi; G, Chan; T, Dubeau; N, Raje; A, Yee; E, O'Donnell; ZR, Hunter; JJ, Castillo

doi:10.1200/jco.2018.78.6426

Public

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

Shared by NobleBlocks on Jul 25, 2018 • 12:00 AM UTC

Authors:

Treon SP

Gustine J

Meid K

Abstract

Purpose Ibrutinib is active in previously treated Waldenström macroglobulinemia (WM). MYD88 mutations ( MYD88<sup>MUT</sup>) and CXCR4 mutations ( CXCR4<sup>MUT</sup>) affect ibrutinib response. We report on a prospective study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!